The leukemia drug alemtuzumab was more effective than interferon (IFN) beta-1a in reducing clinical relapses and slowing disability and loss of brain volume in patients with multiple sclerosis (MS) during recent multinational trials.
Alemtuzumab, an anti-CD52 antibody originally developed as a treatment for B-cell chronic lymphocytic leukemia under the trade name Campath (Genzyme), was the first drug shown to be superior to IFN beta-1a (Rebif, EMD Serono/Pfizer) for improving disability